The key efficacy endpoint was transform from baseline MADRS score. This short-time period examine uncovered that, compared to intranasal placebo furthermore oral antidepressant, intranasal esketamine along side an oral antidepressant appreciably enhanced depressive signs or symptoms right after 4 weeks by a necessarily mean big difference of 4 poin